Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-8055. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-8055 SCHEMBL2929203 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL7861478 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL29396804 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL29388315 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL19263472 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL24264610 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL7861464 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL298416 | 1.00 | MTOR (1.00) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL4409051 | 0.96 | MTOR (0.92) | MTORFECHPIK3R1PIK3CAKCNH2 | |
| Azd-8055 SCHEMBL4408875 | 0.96 | MTOR (0.92) | MTORFECHPIK3R1PIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196676-A1 | TREATING TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2023-10-12 | — | — | WO | claimed |
| US-11622965-B2 | Methods for treating lymphoid malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2023-04-11 | — | — | US | claimed |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-3860575-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | Race Oncology Ltd. (AU) | 2021-08-11 | — | — | EP | claimed |
| US-20200289517-A1 | Methods for Treating Lymphoid Malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2020-09-17 | — | — | US | claimed |
| EP-3700532-A1 | METHODS FOR TREATING LYMPHOID MALIGNANCIES | Zhejiang Dtrm Biopharma Co. Ltd. (CN) | 2020-09-02 | — | — | EP | claimed |
| WO-2020072948-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD. (AU) | 2020-04-09 | — | — | WO | claimed |
| EP-3471735-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang Dtrm Biopharma Co. Ltd. (CN) | 2019-04-24 | — | — | EP | claimed |
| WO-2017218844-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2017-12-21 | — | — | WO | claimed |
| EP-2675450-B1 | COMBINATIONS OF THERAPEUTIC AGENTS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2016-02-10 | — | — | EP | claimed |
| JP-2011512395-A | — | — | 2011-04-21 | — | — | JP | claimed |
| US-20110028471-A1 | COMBINATION THERAPY 238 | ASTRAZENECA AB (SE) | 2011-02-03 | — | — | US | claimed |
| EP-2262504-A1 | COMBINATION THERAPY 238 | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009104019-A1 | COMBINATION THERAPY 238 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | claimed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20090318434-A1 | COMPOSITION AND PROCESS - 356 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| WO-2009153597-A2 | COMPOSITION AND PROCESS - 356 | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009104019-A1 | COMBINATION THERAPY 238 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622965-B2 | Methods for treating lymphoid malignancies | BTK, BCL6, BCL6B | MTOR 995/4885FECH 4402/4885PIK3R1 427/4885 |
| US-20200289517-A1 | Methods for Treating Lymphoid Malignancies | BTK, BCL6, BCL6B | MTOR 995/4885FECH 4402/4885PIK3R1 427/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | MTOR 4823/4885FECH 3798/4885PIK3R1 2623/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | MTOR 4582/4885FECH 1057/4885PIK3R1 2826/4885 |
| US-20110028471-A1 | COMBINATION THERAPY 238 | MTOR, KDR, MET | MTOR 1/4885FECH 2523/4885PIK3R1 100/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | MTOR 4823/4885FECH 3798/4885PIK3R1 2623/4885 |
| US-20090318434-A1 | COMPOSITION AND PROCESS - 356 | FH, CS, SDHB | MTOR 1327/4885FECH 51/4885PIK3R1 3820/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | MTOR 4841/4885FECH 3680/4885PIK3R1 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.